Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs Primary Clinic (Direct GLP)

Medro
Graded #256

Lower grade

vs+5.100000000000001
Primary Clinic (Direct GLP)
Graded #145

Higher grade

The verdict

Primary Clinic (Direct GLP) takes it — 68.7/100 to 63.6/100.

Primary Clinic (Direct GLP) grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePrimary Clinic (Direct GLP) +28
50
78
Dose & formulationMedro +23
77
54
Clinical oversightPrimary Clinic (Direct GLP) +4
71
75
Labs & monitoringPrimary Clinic (Direct GLP) +24
52
76
FulfillmentMedro +19
92
73
Contract termsPrimary Clinic (Direct GLP) +8
33
41
Medro · left barPrimary Clinic (Direct GLP) · right bar

The numbers

MetricMedroPrimary Clinic (Direct GLP)
WeighScore63.6/10068.7/100
GradeCC
Scorecard rank#256#145
Semaglutide$199/mo (compounded)$65/mo (0.25 mg dose, promotional rate, compounded)
Tirzepatide$299/mo (compounded)$110/mo (2.5 mg dose, promotional rate, compounded)
CoverageAll 50 states10 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medro

Graded #256 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Strengths

  • Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
  • GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
  • Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
  • Routine labs and thousands of medications included in membership — no surprise bills
  • Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide

Where it loses points

  • 10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
  • Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
  • 503A pharmacy partners not named
  • LegitScript certification not mentioned on the site
  • Medical director and corporate legal entity not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard